tiprankstipranks
Trending News
More News >
Nureca Ltd. (IN:NURECA)
:NURECA
India Market
Advertisement

Nureca Ltd. (NURECA) AI Stock Analysis

Compare
0 Followers

Top Page

IN:NURECA

Nureca Ltd.

(NURECA)

Rating:46Neutral
Price Target:
₹247.00
▼(-4.61% Downside)
Nureca Ltd.'s overall stock score is primarily impacted by its financial performance, which shows strong equity but significant challenges in profitability and cash flow. Technical analysis indicates a bearish trend, and valuation is unattractive due to a highly negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)

Nureca Ltd. Business Overview & Revenue Model

Company DescriptionNureca Ltd. (NURECA) is a company operating in the healthcare and wellness sector, focusing on providing a wide range of products that enhance health and well-being. The company is known for its offerings in categories such as chronic disease management, lifestyle products, and healthcare devices. Nureca's core product lineup includes devices like blood pressure monitors, thermometers, nebulizers, and other diagnostic and monitoring equipment aimed at both consumer and professional segments.
How the Company Makes MoneyNureca Ltd. generates revenue primarily through the sale of its healthcare and wellness products. Its revenue streams are diversified across multiple product categories, including chronic disease management devices, lifestyle products, and healthcare monitoring equipment. The company sells these products through various distribution channels, including online platforms and retail networks, which helps in reaching a broad customer base. Strategic partnerships with e-commerce platforms enhance its market penetration and sales reach, contributing significantly to its earnings. Additionally, Nureca may engage in partnerships with healthcare providers or institutions to expand its market presence and drive sales.

Nureca Ltd. Financial Statement Overview

Summary
Nureca Ltd. faces mixed financial health with strong equity positions and controlled debt levels. However, declining revenues, negative profitability, and cash flow challenges present significant hurdles. Improvements in operational efficiency and cash management are needed to stabilize and enhance financial performance.
Income Statement
40
Negative
Nureca Ltd. has shown volatile revenue trends with a decline in revenue from 2022 to 2025. The gross profit margin remains moderate at approximately 38% in 2025, but net profitability is a concern with fluctuating net income, swinging to losses in recent periods. The EBIT margin is negative, indicating operational challenges. EBITDA shows improvement in 2025 compared to previous years, but overall performance remains inconsistent.
Balance Sheet
65
Positive
Nureca Ltd.'s balance sheet showcases strong equity with a high equity ratio of around 92% in 2025, indicating low leverage. The debt-to-equity ratio is favorable, suggesting prudent debt management. However, declining total assets over recent periods may signal underlying issues in asset management or utilization.
Cash Flow
35
Negative
The cash flow analysis reveals a challenging financial position with negative free cash flow growth and operating cash flow. The free cash flow to net income ratio is unfavorable, highlighting inefficiencies in converting income to cash. Despite some capital investment, liquidity remains a concern.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.10B1.10B919.28M1.11B2.56B2.13B
Gross Profit331.80M231.33M311.42M355.94M1.23B1.14B
EBITDA48.95M48.95M2.41M-79.04M632.04M636.83M
Net Income8.46M8.46M-17.94M-82.50M449.60M463.74M
Balance Sheet
Total Assets2.10B2.10B2.05B2.07B2.19B1.86B
Cash, Cash Equivalents and Short-Term Investments736.29M1.30B1.14B1.02B927.10M1.27B
Total Debt49.66M49.66M25.16M33.27M44.05M38.85M
Total Liabilities156.91M156.91M120.54M116.97M159.32M226.54M
Stockholders Equity1.94B1.94B1.93B1.95B2.03B1.63B
Cash Flow
Free Cash Flow0.00-234.06M-37.98M98.31M-46.00M341.40M
Operating Cash Flow0.00-190.83M-27.12M102.27M13.99M348.67M
Investing Cash Flow0.0084.39M175.76M-164.56M-30.89M-1.10B
Financing Cash Flow0.00-1.69M-13.03M-15.07M-73.02M923.39M

Nureca Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price258.95
Price Trends
50DMA
256.77
Negative
100DMA
255.23
Negative
200DMA
267.46
Negative
Market Momentum
MACD
-2.30
Negative
RSI
57.92
Neutral
STOCH
25.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Positive. The current price of 258.95 is above the 20-day moving average (MA) of 238.80, above the 50-day MA of 256.77, and below the 200-day MA of 267.46, indicating a neutral trend. The MACD of -2.30 indicates Negative momentum. The RSI at 57.92 is Neutral, neither overbought nor oversold. The STOCH value of 25.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
₹37.92B27.71
1.54%5.89%-1.30%
65
Neutral
₹27.17B29.10
0.40%2.12%-25.99%
61
Neutral
₹30.44B141.32
-7.29%
51
Neutral
$7.92B-0.43-41.69%2.21%22.29%-1.85%
49
Neutral
₹39.93B
0.08%71.72%-125.44%
47
Neutral
₹25.24B96.22
0.54%-8.28%-246.17%
46
Neutral
₹2.59B341.37
35.84%-100.52%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:NURECA
Nureca Ltd.
256.35
-82.30
-24.30%
IN:ADVENZYMES
Advanced Enzyme Technologies Ltd
340.25
-101.07
-22.90%
IN:INDOCO
Indoco Remedies Limited
272.70
-98.08
-26.45%
IN:MOREPENLAB
Morepen Laboratories Limited
49.31
-44.36
-47.36%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
664.30
-118.35
-15.12%
IN:ZOTA
Zota Health Care Ltd.
1,344.50
681.06
102.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 04, 2025